Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Fabrice Andre, MD, PhD is a medical oncologist who is currently director of INSERM Unit U981, a laboratory dedicated to the development of personalized medicine. He is also associate professor in the department of medical oncology, Institut Gustave Roussy, Villejuif, France. His main research topic is translational oncology and development of targeted agents in breast cancer.
He received his medical degree in 2002 and his PhD in 2005 (biotechnologies). He spent one year as visiting assistant professor at the University of Texas, MD Anderson Cancer Center, USA. He is a past recipient of Young Investigator and Career Development awards from the American Society of Clinical Oncology (ASCO). He has published more than 100 peer reviewed papers, including papers in the New England Journal of Medicine, Lancet, Nature Medicine, Journal of Clinical Oncology and Lancet Oncology, either as main or co-author.
He is currently chairing a large team focused on the development of personalized medicine. His lab includes 40 employees working on basic sciences, bioinformatics, biotechnologies and clinical research, and he also is leading two large clinical programs. SAFIR01 is a prospective trial to be conducted between 2011 and 2014, that is evaluating the use of high throughput technologies for the selection of patients to targeted agents. This project will include 400 patients with metastatic breast cancer. CANTO is a prospective cohort that will include 20,000 women who presented with early stage breast cancer and aims to identify predictive parameters for toxicity.
Steven T. Rosen
Steven Rosen, MD, FACP, is Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine, Northwestern University, USA, and Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Director of Cancer Programs at Northwestern Memorial Hospital. Following his graduation with distinction from Northwestern University Medical School's Six-Year Honors Program in 1976, Dr Rosen completed his residency in Internal Medicine at Northwestern and a fellowship in Medical Oncology at the National Cancer Institute, USA. Dr Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies. Dr Rosen has received numerous grants awards and contracts and has published more than 200 scientific papers. As Director of the Cancer Center, Dr Rosen has successfully competed for an NCI Cancer Center Support Grant, NCI grants for his laboratory research, an NCI RAID Contract grant for the development of a novel purine analog, and grants from the Leukemia and Lymphoma Society of America and the American Cancer Society.
Dr Rosen serves on several editorial boards and is editor of Cancer Treatment & Research and Oncology News International. He is a member of all major national associations that focus on oncology and has held leadership positions in the Eastern Cooperative Oncology Group, the American Association of Cancer Institutes and the National Comprehensive Cancer Network. He serves on the advisory boards of several NCI-designated Cancer Centers, the Leukemia and Lymphoma Society of America, the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation and the Wendy Will Cancer Research Foundation. He has also served as an advisor to the UK's Cancer Research Campaign. Dr Rosen was the recipient of Northwestern University Medical School's Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996) and recognition from the Women's Board of Northwestern Memorial Hospital for Compassionate Care (1996). He is acknowledged in Best Doctors and Oncologists in America, and Best Doctors in Chicago.
Marc Sanson, MD, PhD is Professor at P&M Curie University, Department of Neurology and Neuro-oncology, Pitié-Salpêtrière Hospital, in Paris, France.
Dr Sanson has published numerous research articles on neuro-oncology, including more than 100 papers dedicated to gliomas, as well as book chapters, and is a frequently requested lecturer on this topic. His main interest is focused on clinical and translational research on gliomas, including novel therapies, genetic alterations and new biomarkers.
He is a reviewer on a number of journals, including the Journal of Clinical Oncology, Lancet, Annals of Neurology, Neurology, Cancer, Clinical Cancer Research, and Cancer Research.
Dr Sanson earned his MD at University R Descartes and his PhD at University D Diderot, both in Paris, France. He completed a residency in Neurology in Paris, and a post-doc at McGill University, Canada.
Miguel A. Sanz
Miguel Sanz is Head at the Department of Hematology and Bone Marrow Transplant Unit at the University Hospital La Fe in Valencia, Spain, as well as Associate Professor of Medicine at the University of Valencia, Spain. After earning his medical degree at the University of Salamanca in Spain, he was intern, resident and subsequently completed a fellowship in Hematology at the University Hospital La Fe. Professor Sanz is Chairman of the Spanish PETHEMA Group and of the Working Parties of Acute Promyelocytic Leukemia, Acute Myeloid Leukemia and Infections in Neutropenic Patients. He is currently a reviewer for numerous high-profile medical journals, and has authored more than 400 papers, 80 book chapters, and in excess of 950 abstracts at national and international meetings.